Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B

Trial Profile

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Nonacog beta pegol (Primary)
  • Indications Haemophilia B
  • Focus Therapeutic Use
  • Acronyms Paradigm™4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 06 Jun 2017 According to a media release, the company expects to launch Refixia in the first Europe
    • 06 Jun 2017 According to a Novo Nordisk media release, based on the results from the paradigm clinical trial programme (see profiles 243891, 243935, 243947,243961 and 244049) and the positive opinion provided on 24 March 2017 by the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorisation for Refixia for the treatment of adolescents and adults with haemophilia B.
    • 05 Jun 2017 According to a Novo Nordisk media release, based on the results from the paradigm clinical trial programme (see profiles 243891, 243935, 243947,243961 and 244049) U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top